archer material (ASX:AXE) announced progress in the development of graphene field-effect transistor (gFET) sensors for biochip technology, a platform aimed at revolutionizing chronic kidney disease diagnosis. The company’s recent tests have strengthened its operational stability and design, moving it closer to the feasibility stage of product development.

Biochip’s gFET sensor is designed to measure potassium levels in the blood, a key factor in the diagnosis and management of chronic kidney disease. Archer’s team developed an electrical conditioning procedure that significantly increases measurement reproducibility by up to 10 times. This improvement reduces variation in voltage response, a key parameter for achieving accurate potassium measurements. Benchmark experiments conducted with RMIT University further validated gFET’s performance against other biosensors.

“The Archer team has made important advances in bringing biochips to a stage of feasibility and improving the accuracy of testing blood potassium levels in chronic kidney disease,” said Greg English, executive chairman of Archer. These developments are key to the ultimate goal of biochips.” Biochips bring chronic kidney disease testing into the home and improve patient outcomes through better diagnosis and treatment. ”

Archer’s efforts also include creating datasets to assess the stability and batch-to-batch reproducibility of sensors from foundry partners. These datasets will inform feasibility programs and guide ongoing sensor design and manufacturing improvements to meet clinical standards.